Common GLP-1 meds include: Semaglutide (Ozempic, Wegovy) Tirzepatide (Mounjaro, Zepbound) Liraglutide (Saxenda, Victoza) Dulaglutide (Trulicity) When comparing Mounjaro vs
What published clinical research shows: The STEP-1 trial (semaglutide, published in NEJM 2021) demonstrated that participants with obesity or overweight without diabetes who received semaglutide 2.4 mg weekly plus lifestyle intervention experienced mean weight loss of 14.9% over 68 weeks
There is no established waiting period, because there is no direct pharmacological interaction requiring one
It shows decreases in fasting glucose, reduced hemoglobin A1c, and reduced insulin resistance
When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis
Recently, however, there has been a growing trend of "microdosing" GLP-1s, a practice that involves using smaller-than-prescribed doses of these drugs